How to monitor cardiac toxicity of chemotherapy: time is muscle!

Heart. 2014 Aug;100(15):1208-17. doi: 10.1136/heartjnl-2013-303815. Epub 2013 Dec 17.

Authors

D Kerkhove¹, C Fontaine², S Droogmans¹, J De Greve², K Tanaka³, Nico Van De Veire⁴, Guy Van Camp¹

Affiliations

¹ Centrum voor Hart, en Vaatziekten, Universitair Ziekenhuis Brussel Laarbeeklaan, Brussels, Belgium.
² Borstkliniek, Oncologisch centrum, Universitair Ziekenhuis Brussel, VUB, Jette, Brussels, Belgium.
³ Department of Radiology, Universitair Ziekenhuis Brussel-VUB, Jette, Brussels, Belgium.
⁴ Centrum voor Hart, en Vaatziekten, Universitair Ziekenhuis Brussel Laarbeeklaan, Brussels, Belgium Algemeen ziekenhuis Maria Middelares, Ghent, Belgium.

PMID: 24345392
DOI: 10.1136/heartjnl-2013-303815

No abstract available

Keywords: IMAGING AND DIAGNOSTICS.

Publication types

Review

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Diagnostic Imaging / methods
Electrocardiography
Heart Diseases* / chemically induced
Heart Diseases* / diagnosis
Heart Diseases* / physiopathology
Humans
Monitoring, Physiologic / methods*
Neoplasms / drug therapy*
Time Factors
Ventricular Function / drug effects*

Substances

Antineoplastic Agents